Welcome to a special edition of IDEA Collider’s “Deep Medicine” series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine.
Listen on
Spotify – https://open.spotify.com/episode/6cKGBtZPpuBIwbCR3zPjDT
With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new FDA prioritizations and breakthrough clinical data.
Athina shares insights from her meta-analysis on psilocybin and discusses the unique methodological challenges facing the industry, such as blinding integrity and the influence of expectancy effects in clinical trials. We explore the debate over whether the “psychedelic experience” is necessary for therapeutic benefit and how biotechs are balancing regulatory-friendly trial designs with patient safety.
Finally, Athina looks toward the future of precision psychiatry, examining the role of biomarkers and the immense logistical challenges of scaling these intensive therapies within global healthcare systems.
